论文部分内容阅读
目的探讨郝赛汀治疗HER-2阳性转移性乳腺癌临床疗效。方法将驻马店市中心医院2008年2月至2010年2月收治的172例转移性乳腺癌患者随机分为常规组58例、单药组50例、联合组64例,观察3组临床疗效。结果常规组有效率(RR)27.6%,单药组有效率44.0%,联合组有效率59.4%。结论单用还是联合化疗,赫赛汀都是一个治疗乳腺癌转移的重要药物;联合化疗能显著提高患者的缓解率,延长疾病进展时间,延长存活率,较单用疗效更良好。
Objective To investigate the clinical efficacy of haosuetin in the treatment of HER-2 positive metastatic breast cancer. Methods 172 cases of metastatic breast cancer admitted from February 2008 to February 2010 in Zhumadian Central Hospital were randomly divided into conventional group (58 cases), single drug group (50 cases) and combined group (64 cases). The clinical efficacy of the three groups were observed. Results The effective rate (RR) was 27.6% in the conventional group, 44.0% in the single drug group and 59.4% in the combined group. Conclusions Herceptin is an important drug for the treatment of breast cancer metastasis alone or combined with chemotherapy. Combination chemotherapy can significantly improve the patients’ remission rate, prolong the disease progression time and extend the survival rate, which is better than the single therapy.